Kronos Bio, Inc.: directors' dealings · United States · SEC (Form 4)

About Kronos Bio, Inc.

Kronos Bio, Inc. is a U.S.-listed biopharmaceutical company traded on the Nasdaq under ticker KRON, placing it squarely on the NASDAQ market in the United States. The company was incorporated in Delaware on June 2, 2017, and built its business around a focused scientific thesis: targeting deregulated transcription, a disease biology that is implicated in cancer and, in broader research terms, autoimmune disorders as well. Kronos Bio’s historical footprint included a corporate headquarters in San Mateo, California, and a research facility in Cambridge, Massachusetts, a common structure for U.S. biotechs that combine executive and financing functions with proximity to major life-science talent and academic ecosystems. From an operating perspective, Kronos Bio has been a clinical-stage biopharmaceutical developer rather than a commercial-stage revenue producer. Its core activity has centered on discovering and advancing small-molecule therapeutics designed to modulate transcriptional regulatory networks. The company’s public pipeline has included clinical and preclinical assets, with programs such as KB-0742, an orally bioavailable CDK9 inhibitor developed for transcriptionally addicted solid tumors, and earlier-stage programs including lanraplenib and additional internally discovered candidates. This strategy reflects a differentiated, mechanism-driven approach: instead of competing broadly in crowded oncology categories, Kronos Bio aimed at biologically validated but technically challenging targets that may offer selective therapeutic leverage. In competitive terms, Kronos Bio has operated in one of the most competitive segments of biotechnology: small-cap oncology and precision medicine. Its competitive standing has depended less on scale and more on scientific differentiation, translational execution, and capital discipline. Against larger pharmaceutical companies and better-capitalized peers, Kronos Bio’s value proposition was tied to its proprietary discovery engine, its focus on transcription biology, and its ability to move assets through early clinical development. Like many clinical-stage biotechs, however, it faced the usual constraints of high R&D spending, binary clinical risk, and reliance on external financing or strategic alternatives. Recent developments are highly material for investors. In May 2025, Kronos Bio announced a definitive merger agreement with Concentra Biosciences under which Concentra would acquire the company for $0.57 in cash per share plus a contingent value right linked to select assets and cost savings. The company also signaled further cost rationalization, including lease-related actions, underscoring a broader push to preserve value. For French, Belgian, and Swiss investors, KRON should therefore be viewed primarily as a special situation in the U.S. small-cap biotech universe rather than as a straightforward growth story: the key drivers are transaction completion, residual value realization, and any remaining optionality embedded in the pipeline.